COCP - Cocrystal Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Cocrystal Pharma, Inc.

1860 Montreal Road
Tucker, GA 30084
United States

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Gary L. WilcoxCo-Founder, Chairman & CEO136.95kN/A1947
Dr. Sam LeeCo-Founder & Pres200.84kN/A1960
Mr. James J. Martin CPA, M.B.A., CPA, MBACFO & Corp. Sec.230.84kN/A1967
Dr. Roger D. KornbergCo-Founder, Chairman of Scientific Advisory Board & Chief ScientistN/AN/A1947
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of various antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza. It is also involved in identifying and developing various non-nucleoside polymerase inhibitors for norovirus gastroenteritis. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck & Co., Inc. to discover and develop proprietary influenza A/B antiviral agents; and a collaboration agreement National Institute of Health. The company was founded in 2007 and is headquartered in Tucker, Georgia.

Corporate Governance

Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.